Association of tumor necrosis factor-α -308 G/A gene polymorphism with coronary artery diseases: An evidence-based

Elaheh Kazemi1,2, Khadijeh Jamialahmadi3,4, Amir Avan5

  • 1Department of Biochemistry, International Campus of Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Insights

The Tumor necrosis factor-alpha (TNF-α) 308G/A gene variant is linked to coronary artery disease (CAD) risk. Specifically, the AA genotype is associated with increased CAD risk and higher C-reactive protein levels.

Area of Science:

  • Genetics
  • Cardiology
  • Molecular Biology

Background:

  • Coronary artery disease (CAD) is a leading global cause of mortality.
  • Identifying molecular markers for CAD risk is crucial.
  • Tumor necrosis factor-alpha (TNF-α) plays a significant role in CAD development.

Purpose of the Study:

  • To investigate the association between the TNF-α 308 (G/A) gene polymorphism and CAD.
  • To determine if this polymorphism correlates with disease severity and biochemical markers.

Main Methods:

  • Analyzed TNF-α 308 gene polymorphism in 903 individuals (222 controls, 681 CAD patients).
  • Assessed CAD severity via angiography (≥50% vs. <50% stenosis).
  • Evaluated biochemical profiles including lipids, glucose, and C-reactive protein (CRP).

Main Results:

  • TNF-α-AA or AG genotypes were less frequent in CAD patients compared to controls.
  • The TNF-α-308-AA genotype showed a 3.56-fold increased risk of CAD (≥50% stenosis).
  • This genotype was also associated with higher blood pressure and CRP levels in CAD patients.

Conclusions:

  • The TNF-α-308G/A polymorphism is associated with obstructive CAD.
  • Further research is warranted to explore the link between this polymorphism and hypertension.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.7K